Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2014 1
2015 1
2021 2
2023 1
2024 2
2025 2
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles.
Lai X, Yao F, An Y, Li X, Yang XD. Lai X, et al. Molecules. 2023 Mar 11;28(6):2556. doi: 10.3390/molecules28062556. Molecules. 2023. PMID: 36985529 Free PMC article.
In this study, we constructed a novel nanotherapeutic agent (PDL1-NP-FEXO) for cancer immunotherapy by attaching PD-L1 aptamers to albumin nanoparticles that were loaded with H1-antihitamine fexofenadine (FEXO). ...Similar to free PD-L1 aptamer, PDL1-NP could …
In this study, we constructed a novel nanotherapeutic agent (PDL1-NP-FEXO) for cancer immunotherapy by attaching PD-L1 aptamers to al …
Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson's disease.
Kim JB, Kim Y, Kim SJ, Ha TY, Kim DK, Kim DW, So M, Kim SH, Woo HG, Yoon D, Park SM. Kim JB, et al. J Neuroinflammation. 2024 Feb 21;21(1):53. doi: 10.1186/s12974-024-03041-7. J Neuroinflammation. 2024. PMID: 38383441 Free PMC article.
In several animal models, including the 6-OHDA, PFF injection, and C. elegans models, fexofenadine ameliorated PD-related pathologies. RNA-seq analysis and the subsequent experiments suggested that fexofenadine is effective in PD via inhibition of peri …
In several animal models, including the 6-OHDA, PFF injection, and C. elegans models, fexofenadine ameliorated PD-related path …
Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma.
Salmerón C, Tomás Bort E, Sriram K, Javadi-Paydar M, Smitham JE, Pham K, Grose RP, McCormick PJ, DiNardo A, Weitz J, Tiriac H, Lowy AM, Insel PA. Salmerón C, et al. J Pharmacol Exp Ther. 2025 May;392(5):103573. doi: 10.1016/j.jpet.2025.103573. Epub 2025 Apr 4. J Pharmacol Exp Ther. 2025. PMID: 40288207 Free article.
HRH1 activation increases migration and invasion by PDAC cancer cells. Orally administered fexofenadine, an H1-antihistamine, was bioavailable in the tumors of KPC mice and yielded smaller pancreatic tumor tissue weights and lower expression of immunomodulatory (interleuki …
HRH1 activation increases migration and invasion by PDAC cancer cells. Orally administered fexofenadine, an H1-antihistamine, was bio …
Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol.
Brannan JD, Anderson SD, Gomes K, King GG, Chan HK, Seale JP. Brannan JD, et al. Am J Respir Crit Care Med. 2001 May;163(6):1420-5. doi: 10.1164/ajrccm.163.6.2006019. Am J Respir Crit Care Med. 2001. PMID: 11371412 Clinical Trial.
Fexofenadine reduced sensitivity to mannitol and the PD(15) was (mean [95% confidence interval] 138 [95, 201]) mg versus placebo (51 [25, 106] mg) (p < 0.001). The final percent reduction in FEV(1) with fexofenadine was 20.8 +/- 5.4% and not different from …
Fexofenadine reduced sensitivity to mannitol and the PD(15) was (mean [95% confidence interval] 138 [95, 201]) mg versus place …
A Perception-Based Survey on Practice Patterns Pertaining to the Diagnosis and Management of Allergic Rhinitis in India.
Gupte V, Thakur G, Upadhyaya A, Jain S, Bhargava S. Gupte V, et al. Cureus. 2024 Feb 27;16(2):e55032. doi: 10.7759/cureus.55032. eCollection 2024 Feb. Cureus. 2024. PMID: 38550471 Free PMC article.
For the management of mild cases of seasonal or perennial AR, 980 (60.9%) physicians preferred fexofenadine as an oral antihistamine of choice. Fluticasone furoate was the preferred intranasal corticosteroid (INCS) option (67.1% of physicians (n=1079)), for the management …
For the management of mild cases of seasonal or perennial AR, 980 (60.9%) physicians preferred fexofenadine as an oral antihistamine …
Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.
Thomson BK, Nolin TD, Velenosi TJ, Feere DA, Knauer MJ, Asher LJ, House AA, Urquhart BL. Thomson BK, et al. Am J Kidney Dis. 2015 Apr;65(4):574-82. doi: 10.1053/j.ajkd.2014.09.015. Epub 2014 Nov 21. Am J Kidney Dis. 2015. PMID: 25453994
SETTING & PARTICIPANTS: Healthy controls (n=8), patients with non-dialysis-dependent (NDD)-CKD (n=8), and patients receiving HD (n=10) or PD (n=8). OUTCOMES: Exposure to midazolam and fexofenadine were quantified using area under the curve (AUC). ...RESULTS: Mid …
SETTING & PARTICIPANTS: Healthy controls (n=8), patients with non-dialysis-dependent (NDD)-CKD (n=8), and patients receiving HD (n=10) o …
Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine.
Fritz I, Wagner P, Olsson H. Fritz I, et al. Transl Oncol. 2021 Apr;14(4):101029. doi: 10.1016/j.tranon.2021.101029. Epub 2021 Feb 5. Transl Oncol. 2021. PMID: 33550204 Free PMC article.
BACKGROUND: We have previously shown an association with substantially improved survival in breast cancer and melanoma for desloratadine and loratadine users, and set out to find whether an improved survival can be seen in tumors with and without a known response to immune checkp …
BACKGROUND: We have previously shown an association with substantially improved survival in breast cancer and melanoma for desloratadine and …
An oxygen-permeable, stirrer-pump-integrated liver-heart microphysiological system enables time-resolved analysis in PK-PD relationships of metabolism-dependent cardiotoxicity.
Horiuchi S, Oka K, Shinha K, Jinno R, Kochi M, Koda N, Masuo Y, Kimura H, Kato Y, Yamazaki D. Horiuchi S, et al. NAM J. 2026 Jun 29;2:100107. doi: 10.1016/j.namjnl.2026.100107. eCollection 2026. NAM J. 2026. PMID: 42436710 Free PMC article.
Drug concentration analysis by LC-MS/MS showed a marked increase in the formation of the primary metabolite fexofenadine, in the co-culture system, which was consistent with the reduced cardiotoxic potential of this metabolite. ...
Drug concentration analysis by LC-MS/MS showed a marked increase in the formation of the primary metabolite fexofenadine, in the co-c …
LC-MS/MS quantification of omadacycline in human plasma for therapeutic drug monitoring: method development and clinical application.
Wang Y, Diao Z, Qu Y, Fan K, Feng C, Lv B, Yu Y, Geng Z. Wang Y, et al. Sci Rep. 2025 Jul 29;15(1):27728. doi: 10.1038/s41598-025-13396-3. Sci Rep. 2025. PMID: 40730882 Free PMC article.
The ratio of the 24-hour area under the concentration-time curve to minimum inhibitory concentration (AUC(0-24)/MIC) serves as the primary pharmacokinetic/pharmacodynamic (PK/PD) index for omadacycline, demonstrating strong correlation with therapeutic efficacy, particular …
The ratio of the 24-hour area under the concentration-time curve to minimum inhibitory concentration (AUC(0-24)/MIC) serves as the primary p …
Acquired Idiopathic Generalized Anhidrosis as a Late-Onset Immune-Related Adverse Event of Pembrolizumab in a Patient With Lung Adenocarcinoma: A Case Report and Review of the Literature.
Maruyama A, Sotozono A, Fukumoto T. Maruyama A, et al. J Dermatol. 2026 Jul;53(7):1072-1076. doi: 10.1111/1346-8138.70306. Epub 2026 May 11. J Dermatol. 2026. PMID: 42108863 Review.
EGFR, ALK, and ROS1 were negative, and programmed death-ligand 1 (PD-L1) tumor proportion score (TPS; 22C3 antibody) was 90%-100%. Sweat testing revealed anhidrosis exceeding 75% of the body surface. ...The patient was treated with three courses of methylprednisolone pulse …
EGFR, ALK, and ROS1 were negative, and programmed death-ligand 1 (PD-L1) tumor proportion score (TPS; 22C3 antibody) was 90%-100%. Sw …
12 results